An observational study in Obstructive Sleep Apnea (OSAS), sponsored by Karabuk University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Karabuk University · Observational
Among 54 studies in Sleep Apnea, Obstructive with a site in Turkey — 17 open to participants now, 17 under way, 2 of them phase 3. Sleep Apnea, Obstructive · Turkey.
Among the 54 studies in Sleep Apnea, Obstructive with a site in Turkey, this one is the 30th largest by planned enrollment of the 34 observational ones, is one of 10 that started in 2026, is one of 34 observational ones, reaches primary completion later than 9 of the 16 other live ones, and was the 50th registered.
2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
This study's planned enrollment of 47 is below the median of 105 across 666 observational studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →17 of the 54 studies in Sleep Apnea, Obstructive with a site in Turkey are open now, in 12 countries. Each count lists the studies.
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 145 (46%) set no upper age limit and 125 (40%) stop at 75 or younger; 53 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →54 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 10 started in 2026.
Median enrollment 45 across the 20 interventional studies, 79 across the 34 observational. Of the 31 that completed or were terminated, 0 (0%) have results posted.
2 of 54 have an industry lead sponsor. The 10 most frequent:
Karabuk University is the lead sponsor of 143 studies on the registry; 40 are open to participants now.
Karabuk University has 2 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
5 of the studies in Sleep Apnea, Obstructive with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554430Mustafa Kemal UniversityIOS Parameters and PAP Titration Pressure in Obstructive Sleep Apnea | 2026-11-30 |
| NCT07743892Karabuk UniversityObstructive Sleep Apnea and Body Awareness | 2027-05-21 |
| NCT07889154Medipol UniversityPhysical Activity, Sleep Quality, and Respiratory Function in Obstructive Sleep Apnea | 2027-06-15 |
| NCT07214636Medipol UniversityDevelopment and Investigation of the ApneaTheraPlay | 2027-09-01 |
| NCT07913139Karabuk UniversityFunctional Capacity in Obstructive Sleep Apnea | 2027-10-28 |
Among the 54 studies in Sleep Apnea, Obstructive with a site in Turkey, from their registry updates:
Obstructive Sleep Apnea Syndrome (OSAS) is a chronic disease characterized by intermittent hypoxia and sleep fragmentation resulting from recurrent upper airway obstructions. The physiological and neurocognitive changes caused by the disease can affect how individuals perceive and interpret bodily sensations. Although body awareness plays a significant role in the perception and management of symptoms, its relationship with clinical parameters in individuals with OSAS has not been sufficiently investigated. Therefore, the aim of our study is to examine the relationship between body awareness and respiratory function, disease severity, fatigue, shortness of breath, and sleep quality in OSAS patients.
Patients with obstructive sleep apnea syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosed with Obstructive Sleep Apnea Syndrome
Body awareness
The Body Awareness Questionnaire (BAQ) will be used to assess individuals' body awareness. The scale score ranges from 18 to 26, with higher scores indicating higher awareness.
Time frame: Baseline
Dyspnea
Dyspnea is assessed with the modified Medical Research Council (mMRC) dyspnea scale. As the score increases, shortness of breath increases.
Time frame: Baseline
Disease severity
The evaluation will be based on the Apnea/Hypopnea index measured by polysomnography. An Apnea-Hypopnea Index \>5 indicates Obstructive Sleep Apnea Syndrome.
Time frame: Baseline
Fatigue severity
Fatigue will be assessed using the Fatigue Severity Scale. A score of 36 or higher indicates severe fatigue.
Time frame: Baseline
Sleep quality
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PUKI). The total score ranges from 0 to 21, and a score above 5 indicates poor sleep quality.
Time frame: Baseline
Pulmonary function (Forced vital capacity (FVC)
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced vital capacity (FVC) will be measured.
Time frame: Baseline
Pulmonary function (Forced expiratory volume in the first second (FEV1)
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced expiratory volume in the first second (FEV1) will be measured.
Time frame: Baseline
Pulmonary function (FEV1 / FVC)
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. FEV1 / FVC will be measured.
Time frame: Baseline
Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%))
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be measured.
Time frame: Baseline
Pulmonary function (Peak flow rate (PEF))
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Peak flow rate (PEF) will be measured.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.